Hamid Hassanzadeh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hamid Hassanzadeh has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
Jon Raso
Department of Orthopaedic Surgery, University of Virginia, Charlottesville, VA, USA
3 shared publicationsLawal Labaran
Department of Orthopaedic Surgery, University of Virginia, Charlottesville, VA, USA
3 shared publicationsPramod N. Kamalapathy
Department of Orthopaedic Surgery, University of Virginia, Charlottesville, VA, USA
3 shared publicationsAditya Bs Joshi
Department of Orthopaedic Surgery, Johns Hopkins University National Capital Region, Bethesda, Maryland, USA
2 shared publicationsKhaled M. Kebaish
Department of Orthopaedic Surgery, Johns Hopkins University National Capital Region, Bethesda, Maryland, USA
2 shared publicationsRachel S. Bronheim
Department of Orthopaedic Surgery, Johns Hopkins University National Capital Region, Bethesda, Maryland, USA
2 shared publications
Latest Publications
- 27 February 2026
- Published by Wolters Kluwer Health in Spine
- Vol. 51  (18) , 1280-1285
Vancomycin Effectiveness in Reducing Surgical Site Infection in Posterior Spinal Fusion Surgery
Study Design.: Retrospective analysis of prospectively collected data. Objective.: To reevaluate vancomycin as a preventive measure for surgical site infection (SSI). Summary of Background Data.: Intrawound vancomycin powder is used to prevent SSIs in spinal surgery. Prior studies, often limited to single institutions or small samples, have shown mixed efficacy and potential increases in non- S. aureus and gram-negative infections. We hypothesized that SSIs rates would be similar with and without intrawound vancomycin in posterior spinal fusion (PSF) surgery. Methods.: Prospectively collected data from the 3,595 patients in the STaphylococcus aureus suRgical Inpatient Vaccine Efficacy (STRIVE) trial were stratified by intrawound antibiotic usage. Multivariate logistic regression assessed the effect of vancomycin use on SSI, adjusting for patient demographics and SSI-associated risk factors. Secondary outcomes included critical care stay, reoperation, sepsis, and hospital readmission. Results.: Of 3,311 patients who underwent surgery, 847 (26%) received only intrawound vancomycin and 1,534 (46%) received no intrawound antibiotics. Sixty (8%) patients developed postoperative SSI, of whom 20 (33%) had received intrawound vancomycin. Receiving intrawound vancomycin was not associated with SSI incidence versus no intrawound antibiotics (odds ratio [OR] = 0.77; 95% confidence interval [CI] 0.42–1.42), critical care stay (OR = 0.94; 95% CI 0.78–1.12), or sepsis (OR 2.04; 95% CI 0.62–6.73). However, intrawound vancomycin was associated with increased odds of hospital readmission (OR 1.82; 95% CI 1.28–2.6; P < .001) and reoperation (OR 1.75; 95% CI 1.18–2.6; P = .005). Factors significantly associated with intrawound vancomycin use included intraoperative antibiotic readministration (OR 2.97; 95% CI 1.36–6.5; P =.006) and hospital location, lower odds in Europe (OR 0.13; 95% CI 0.06–0.29; P < .001) or Asia (OR: 0.02; 95% CI 0–0.08; P < .001) versus North America. Conclusion.: Intraoperative vancomycin use was not associated with reduced SSI incidence compared to no intrawound antibiotics following PSF surgery. Level of Evidence : 2
- 27 February 2026
- Published by Wolters Kluwer Health in Spine
- Vol. 51  (18) , 1280-1285
Vancomycin Effectiveness in Reducing Surgical Site Infection in Posterior Spinal Fusion Surgery
Study Design.: Retrospective analysis of prospectively collected data. Objective.: To reevaluate vancomycin as a preventive measure for surgical site infection (SSI). Summary of Background Data.: Intrawound vancomycin powder is used to prevent SSIs in spinal surgery. Prior studies, often limited to single institutions or small samples, have shown mixed efficacy and potential increases in non- S. aureus and gram-negative infections. We hypothesized that SSIs rates would be similar with and without intrawound vancomycin in posterior spinal fusion (PSF) surgery. Methods.: Prospectively collected data from the 3,595 patients in the STaphylococcus aureus suRgical Inpatient Vaccine Efficacy (STRIVE) trial were stratified by intrawound antibiotic usage. Multivariate logistic regression assessed the effect of vancomycin use on SSI, adjusting for patient demographics and SSI-associated risk factors. Secondary outcomes included critical care stay, reoperation, sepsis, and hospital readmission. Results.: Of 3,311 patients who underwent surgery, 847 (26%) received only intrawound vancomycin and 1,534 (46%) received no intrawound antibiotics. Sixty (8%) patients developed postoperative SSI, of whom 20 (33%) had received intrawound vancomycin. Receiving intrawound vancomycin was not associated with SSI incidence versus no intrawound antibiotics (odds ratio [OR] = 0.77; 95% confidence interval [CI] 0.42–1.42), critical care stay (OR = 0.94; 95% CI 0.78–1.12), or sepsis (OR 2.04; 95% CI 0.62–6.73). However, intrawound vancomycin was associated with increased odds of hospital readmission (OR 1.82; 95% CI 1.28–2.6; P < .001) and reoperation (OR 1.75; 95% CI 1.18–2.6; P = .005). Factors significantly associated with intrawound vancomycin use included intraoperative antibiotic readministration (OR 2.97; 95% CI 1.36–6.5; P =.006) and hospital location, lower odds in Europe (OR 0.13; 95% CI 0.06–0.29; P < .001) or Asia (OR: 0.02; 95% CI 0–0.08; P < .001) versus North America. Conclusion.: Intraoperative vancomycin use was not associated with reduced SSI incidence compared to no intrawound antibiotics following PSF surgery. Level of Evidence : 2
- Open Access
- 1 January 2026
- Published by AME Publishing Company in Journal of Spine Surgery
- Vol. 12  (1) , 2
A retrospective, controlled trial evaluation of pulsed electromagnetic field stimulation for fusion success following lumbar spinal surgery
Background: Spinal surgeries have become common procedures due to greater life expectancy and the increasing elderly population. Failed fusion, or nonunion, may be influenced by patient risk factors and can lead to a myriad of complications. Pulsed electromagnetic field (PEMF) stimulation is a noninvasive post-operative adjunct therapy that has been shown to influence underlying cellular processes that may improve osteogenesis to promote successful fusion following spinal surgery. The aim of the study was to evaluate the effect of PEMF on lumbar fusion in patients with risk factors for nonunion. Methods: The current study employed a prospective, multicenter study to investigate PEMF as an adjunct therapy following lumbar spinal fusion procedures in subjects with risk factors for failed fusion. A retrospective control arm was used as a comparator. Subjects were enrolled with at least one of the following risk factors: prior failed fusion, multi-level fusion, nicotine use, osteoporosis, advanced age (>65 years), body mass index >30 kg/m2, and diabetes. PEMF was delivered for 6-months following surgery. Overall fusion status and influence of risk factors were assessed. Successful fusion was determined by radiographic imaging. Results: Fusion status was compared at a 12-month follow-up in subjects treated with PEMF (n=142) vs. control (n=47). Successful fusion was observed in 88.0% (n=125/142) of PEMF subjects and 68.1% (n=32/47) of control subjects. PEMF therapy resulted in statistically improved fusion rates in subjects with prior failed fusion (P=0.04), multi-level fusion surgery (PConclusions: PEMF therapy improved fusion success in subjects following lumbar spinal surgery and represents a beneficial adjunct treatment resulting in significant improvements in subjects having risk factors for nonunion.
- 1 January 2026
- Published by AME Publishing Company in Journal of Spine Surgery
- Vol. 12  (1) , 2
Open AccessA retrospective, controlled trial evaluation of pulsed electromagnetic field stimulation for fusion success following lumbar spinal surgery
Background: Spinal surgeries have become common procedures due to greater life expectancy and the increasing elderly population. Failed fusion, or nonunion, may be influenced by patient risk factors and can lead to a myriad of complications. Pulsed electromagnetic field (PEMF) stimulation is a noninvasive post-operative adjunct therapy that has been shown to influence underlying cellular processes that may improve osteogenesis to promote successful fusion following spinal surgery. The aim of the study was to evaluate the effect of PEMF on lumbar fusion in patients with risk factors for nonunion. Methods: The current study employed a prospective, multicenter study to investigate PEMF as an adjunct therapy following lumbar spinal fusion procedures in subjects with risk factors for failed fusion. A retrospective control arm was used as a comparator. Subjects were enrolled with at least one of the following risk factors: prior failed fusion, multi-level fusion, nicotine use, osteoporosis, advanced age (>65 years), body mass index >30 kg/m2, and diabetes. PEMF was delivered for 6-months following surgery. Overall fusion status and influence of risk factors were assessed. Successful fusion was determined by radiographic imaging. Results: Fusion status was compared at a 12-month follow-up in subjects treated with PEMF (n=142) vs. control (n=47). Successful fusion was observed in 88.0% (n=125/142) of PEMF subjects and 68.1% (n=32/47) of control subjects. PEMF therapy resulted in statistically improved fusion rates in subjects with prior failed fusion (P=0.04), multi-level fusion surgery (PConclusions: PEMF therapy improved fusion success in subjects following lumbar spinal surgery and represents a beneficial adjunct treatment resulting in significant improvements in subjects having risk factors for nonunion.
- Open Access
- 1 July 2025
- Published by Wolters Kluwer Health in JBJS Open Access
- Vol. 10  (3)
Scholarly Success of Orthopaedic Surgeons Participating in Traveling Fellowships
Background: Orthopaedic traveling fellowship programs provide surgeons with valuable opportunities for professional growth and specialized learning. However, there has been limited research on the impact of such programs on scholarly success and career advancement. The aim of this study was to evaluate the demographic, academic, and scholarly outcomes of traveling fellowship participants. Methods: This study was a retrospective analysis of orthopaedic surgeons who participated in a traveling fellowship program from 1989 to 2024. Demographic and academic characteristics were collected for each traveling fellowship recipient, including residency program attended, fellowship specialty, fellowship institution, academic rank, current practice environment, and leadership roles. The Scopus database was used to determine individual H-indices and number of publications. Other characteristics included board position in a major orthopaedic society, National Institutes of Health (NIH) research funding, Orthopaedic Research and Education Foundation (OREF) grant recipient, advanced degrees, and editorial board position in an orthopaedic journal. Descriptive and regression statistics were used for the study. Results: Of the 558 physicians who participated in an orthopaedic traveling fellowship, demographic and academic information was available for 506 of them (90.7%). Of these, the majority (96.6%) only completed 1 traveling fellowship. Predominantly, recipients were male (90.7%) and White (79.1%) and had completed a sports fellowship (33.0%). Current practicing environment was often academic (76.5%), with most holding the rank of professor (51.0%). Seventy-two participants (14.2%) had a leadership role as chair and 48 (9.5%) were division chiefs. Participants had an average H-index of 35.7 and averaged 169.9 publications. One hundred seventy-three fellowship recipients (34.2%) received an OREF grant and 67 (13.2%) received NIH research funding. Fellowship participants who received an OREF grant or NIH funding were more likely to have a higher faculty rank, higher H-index, and an increase in the number of publications (p < 0.001 for all). Conclusion: The lessons, skills, and knowledge from traveling fellowships appear to play an important role in shaping the academic and scholarly career of orthopaedic surgeons. Level of Evidence: Level IV. See Instructions for Authors for a complete description of levels of evidence.
- 1 July 2025
- Published by Wolters Kluwer Health in JBJS Open Access
- Vol. 10  (3)
Open AccessScholarly Success of Orthopaedic Surgeons Participating in Traveling Fellowships
Background: Orthopaedic traveling fellowship programs provide surgeons with valuable opportunities for professional growth and specialized learning. However, there has been limited research on the impact of such programs on scholarly success and career advancement. The aim of this study was to evaluate the demographic, academic, and scholarly outcomes of traveling fellowship participants. Methods: This study was a retrospective analysis of orthopaedic surgeons who participated in a traveling fellowship program from 1989 to 2024. Demographic and academic characteristics were collected for each traveling fellowship recipient, including residency program attended, fellowship specialty, fellowship institution, academic rank, current practice environment, and leadership roles. The Scopus database was used to determine individual H-indices and number of publications. Other characteristics included board position in a major orthopaedic society, National Institutes of Health (NIH) research funding, Orthopaedic Research and Education Foundation (OREF) grant recipient, advanced degrees, and editorial board position in an orthopaedic journal. Descriptive and regression statistics were used for the study. Results: Of the 558 physicians who participated in an orthopaedic traveling fellowship, demographic and academic information was available for 506 of them (90.7%). Of these, the majority (96.6%) only completed 1 traveling fellowship. Predominantly, recipients were male (90.7%) and White (79.1%) and had completed a sports fellowship (33.0%). Current practicing environment was often academic (76.5%), with most holding the rank of professor (51.0%). Seventy-two participants (14.2%) had a leadership role as chair and 48 (9.5%) were division chiefs. Participants had an average H-index of 35.7 and averaged 169.9 publications. One hundred seventy-three fellowship recipients (34.2%) received an OREF grant and 67 (13.2%) received NIH research funding. Fellowship participants who received an OREF grant or NIH funding were more likely to have a higher faculty rank, higher H-index, and an increase in the number of publications (p < 0.001 for all). Conclusion: The lessons, skills, and knowledge from traveling fellowships appear to play an important role in shaping the academic and scholarly career of orthopaedic surgeons. Level of Evidence: Level IV. See Instructions for Authors for a complete description of levels of evidence.
- 3 September 2024
- Published by Wolters Kluwer Health in Clinical Spine Surgery
- Vol. 38  (3) , 123-131
Trends and Rates of Reporting of Race, Ethnicity, and Social Determinants of Health in Spine Surgery Randomized Clinical Trials
Study Design: A systematic review. Objective: We characterized the rates of sociodemographic data and social determinants of health (SDOH) reported in spinal surgery randomized control trials (RCTs) and the association between these RCTs' characteristics and their rates of reporting on race, ethnicity, and SDOH variables. Summary of Background Data: Although numerous institutions maintain guidelines and recommendations regarding the inclusion and reporting of sociodemographic and SDOH variables in RCTs, the proportion of studies that ultimately report such information is unclear, particularly in spine surgery. Materials and Methods: We searched the MEDLINE, PubMed, and Embase databases for published results from spinal surgery RCTs from January 2002 through December 2022, and screened studies according to prespecified inclusion criteria regarding analysis and reporting of sociodemographic and SDOH variables. Results: We analyzed 421 studies. Ninety-six studies (22.8%) reported race, ethnicity, or SDOH covariates. On multivariate analysis, study size [rate ratio (RR)=1.18; 95% CI, 1.06–1.32], public/institutional funding (RR=2.28; 95% CI, 1.29–4.04), and private funding (RR=3.27; 95% CI, 1.87–5.74) were significantly associated with reporting race, ethnicity, or SDOH variables. Study size (RR=1.26; 95% CI, 1.07–1.48) and North American region (RR=21.84; CI, 5.04–94.64) were associated with a higher probability of reporting race and/or ethnicity. Finally, study size (RR=1.27; 95% CI, 1.10–1.46), public/institutional funding (RR=2.68; 95% CI, 1.33–5.39), focus on rehabilitation/therapy intervention (RR=2.70; 95% CI, 1.40–5.21), and nonblinded study groups (RR=2.70; 95% CI, 1.40–5.21) were associated with significantly higher probability of reporting employment status. Conclusion: Rates of reporting race, ethnicity, and SDOH variables were lower in the spinal surgery RCTs in our study than in RCTs in other medical disciplines. These reporting rates did not increase over a 20-year period. Trial characteristics significantly associated with higher rates of reporting were larger study size, North American region, private or public funding, and a focus on behavioral/rehabilitation interventions. Level of Evidence: Level III.
- 3 September 2024
- Published by Wolters Kluwer Health in Clinical Spine Surgery
- Vol. 38  (3) , 123-131
Trends and Rates of Reporting of Race, Ethnicity, and Social Determinants of Health in Spine Surgery Randomized Clinical Trials
Study Design: A systematic review. Objective: We characterized the rates of sociodemographic data and social determinants of health (SDOH) reported in spinal surgery randomized control trials (RCTs) and the association between these RCTs' characteristics and their rates of reporting on race, ethnicity, and SDOH variables. Summary of Background Data: Although numerous institutions maintain guidelines and recommendations regarding the inclusion and reporting of sociodemographic and SDOH variables in RCTs, the proportion of studies that ultimately report such information is unclear, particularly in spine surgery. Materials and Methods: We searched the MEDLINE, PubMed, and Embase databases for published results from spinal surgery RCTs from January 2002 through December 2022, and screened studies according to prespecified inclusion criteria regarding analysis and reporting of sociodemographic and SDOH variables. Results: We analyzed 421 studies. Ninety-six studies (22.8%) reported race, ethnicity, or SDOH covariates. On multivariate analysis, study size [rate ratio (RR)=1.18; 95% CI, 1.06–1.32], public/institutional funding (RR=2.28; 95% CI, 1.29–4.04), and private funding (RR=3.27; 95% CI, 1.87–5.74) were significantly associated with reporting race, ethnicity, or SDOH variables. Study size (RR=1.26; 95% CI, 1.07–1.48) and North American region (RR=21.84; CI, 5.04–94.64) were associated with a higher probability of reporting race and/or ethnicity. Finally, study size (RR=1.27; 95% CI, 1.10–1.46), public/institutional funding (RR=2.68; 95% CI, 1.33–5.39), focus on rehabilitation/therapy intervention (RR=2.70; 95% CI, 1.40–5.21), and nonblinded study groups (RR=2.70; 95% CI, 1.40–5.21) were associated with significantly higher probability of reporting employment status. Conclusion: Rates of reporting race, ethnicity, and SDOH variables were lower in the spinal surgery RCTs in our study than in RCTs in other medical disciplines. These reporting rates did not increase over a 20-year period. Trial characteristics significantly associated with higher rates of reporting were larger study size, North American region, private or public funding, and a focus on behavioral/rehabilitation interventions. Level of Evidence: Level III.
- Open Access
- 11 April 2024
- Published by Wolters Kluwer Health in Clinical Spine Surgery
- Vol. 37  (4) , 124-130
Adjunctive Use of Bone Growth Stimulation Increases Cervical Spine Fusion Rates in Patients at Risk for Pseudarthrosis
Study Design: A prospective multicenter clinical trial (NCT 03177473) was conducted with a retrospective cohort used as a control arm. Objective: The purpose of this study was to evaluate cervical spine fusion rates in subjects with risk factors for pseudarthrosis who received pulsed electromagnetic field (PEMF) treatment. Summary of Background Data: Certain risk factors predispose patients to pseudarthrosis, which is associated with prolonged pain, reduced function, and decreased quality of life. Methods: Subjects in the PEMF group were treated with PEMF for 6 months postoperatively. The primary outcome measure was fusion status at the 12-month follow-up period. Fusion status was determined using anterior/posterior, lateral, and flexion/extension radiographs and computed tomography (without contrast). Results: A total of 213 patients were evaluated (PEMF, n=160; Control, n=53). At baseline, the PEMF group had a higher percentage of subjects who used nicotine (P=0.01), had osteoporosis (PP65 years of age (P=0.01). The PEMF group showed over two-fold higher percentage of subjects that had ≥3 risk factors (n=92/160, 57.5%) compared with the control group (n=14/53, 26.4%). At the 12-month follow-up, the PEMF group demonstrated significantly higher fusion rates compared with the control (90.0% vs. 60.4%, PP30 kg/m2; P=0.0021) when compared with the control group. No significant safety concerns were observed. Conclusions: Adjunctive use of PEMF stimulation provides significant improvements in cervical spine fusion rates in subjects having risk factors for pseudarthrosis. When compared with control subjects that did not use PEMF stimulation, treated subjects showed improved fusion outcomes despite being older, having more risk factors for pseudarthrosis, and undergoing more complex surgeries.
- 11 April 2024
- Published by Wolters Kluwer Health in Clinical Spine Surgery
- Vol. 37  (4) , 124-130
Open AccessAdjunctive Use of Bone Growth Stimulation Increases Cervical Spine Fusion Rates in Patients at Risk for Pseudarthrosis
Study Design: A prospective multicenter clinical trial (NCT 03177473) was conducted with a retrospective cohort used as a control arm. Objective: The purpose of this study was to evaluate cervical spine fusion rates in subjects with risk factors for pseudarthrosis who received pulsed electromagnetic field (PEMF) treatment. Summary of Background Data: Certain risk factors predispose patients to pseudarthrosis, which is associated with prolonged pain, reduced function, and decreased quality of life. Methods: Subjects in the PEMF group were treated with PEMF for 6 months postoperatively. The primary outcome measure was fusion status at the 12-month follow-up period. Fusion status was determined using anterior/posterior, lateral, and flexion/extension radiographs and computed tomography (without contrast). Results: A total of 213 patients were evaluated (PEMF, n=160; Control, n=53). At baseline, the PEMF group had a higher percentage of subjects who used nicotine (P=0.01), had osteoporosis (PP65 years of age (P=0.01). The PEMF group showed over two-fold higher percentage of subjects that had ≥3 risk factors (n=92/160, 57.5%) compared with the control group (n=14/53, 26.4%). At the 12-month follow-up, the PEMF group demonstrated significantly higher fusion rates compared with the control (90.0% vs. 60.4%, PP30 kg/m2; P=0.0021) when compared with the control group. No significant safety concerns were observed. Conclusions: Adjunctive use of PEMF stimulation provides significant improvements in cervical spine fusion rates in subjects having risk factors for pseudarthrosis. When compared with control subjects that did not use PEMF stimulation, treated subjects showed improved fusion outcomes despite being older, having more risk factors for pseudarthrosis, and undergoing more complex surgeries.
- Open Access
- 1 May 2023
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 77  (2) , 312-320
Efficacy of a 4-Antigen Staphylococcus aureus Vaccine in Spinal Surgery: The STaphylococcus aureus suRgical Inpatient Vaccine Efficacy (STRIVE) Randomized Clinical Trial
Staphylococcus aureus is a global pathogen that is frequently responsible for healthcare-associated infections, including surgical site infections (SSIs). Current infection prevention and control approaches may be limited, with S. aureus antibiotic resistance remaining problematic. Thus, a vaccine to prevent or reduce S. aureus infection is critically needed. We evaluated the efficacy and safety of an investigational 4-antigen S. aureus vaccine (SA4Ag) in adults undergoing elective open posterior spinal fusion procedures with multilevel instrumentation. In this multicenter, site-level, randomized, double-blind trial, patients aged 18–85 years received a single dose of SA4Ag or placebo 10–60 days before surgery. SA4Ag efficacy in preventing postoperative S. aureus bloodstream infection and/or deep incisional or organ/space SSIs was the primary end point. Safety evaluations included local reactions, systemic events, and adverse events (AEs). Immunogenicity and colonization were assessed. Study enrollment was halted when a prespecified interim efficacy analysis met predefined futility criteria. SA4Ag showed no efficacy (0.0%) in preventing postoperative S. aureus infection (14 cases in each group through postoperative day 90), despite inducing robust functional immune responses to each antigen compared with placebo. Colonization rates across groups were similar through postoperative day 180. Local reactions and systemic events were mostly mild or moderate in severity, with AEs reported at similar frequencies across groups. In patients undergoing elective spinal fusion surgical procedures, SA4Ag was safe and well tolerated but, despite eliciting substantial antibody responses that blocked key S. aureus virulence mechanisms, was not efficacious in preventing S. aureus infection. Clinical Trials Registration. NCT02388165.
- 1 May 2023
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 77  (2) , 312-320
Open AccessEfficacy of a 4-Antigen Staphylococcus aureus Vaccine in Spinal Surgery: The STaphylococcus aureus suRgical Inpatient Vaccine Efficacy (STRIVE) Randomized Clinical Trial
Staphylococcus aureus is a global pathogen that is frequently responsible for healthcare-associated infections, including surgical site infections (SSIs). Current infection prevention and control approaches may be limited, with S. aureus antibiotic resistance remaining problematic. Thus, a vaccine to prevent or reduce S. aureus infection is critically needed. We evaluated the efficacy and safety of an investigational 4-antigen S. aureus vaccine (SA4Ag) in adults undergoing elective open posterior spinal fusion procedures with multilevel instrumentation. In this multicenter, site-level, randomized, double-blind trial, patients aged 18–85 years received a single dose of SA4Ag or placebo 10–60 days before surgery. SA4Ag efficacy in preventing postoperative S. aureus bloodstream infection and/or deep incisional or organ/space SSIs was the primary end point. Safety evaluations included local reactions, systemic events, and adverse events (AEs). Immunogenicity and colonization were assessed. Study enrollment was halted when a prespecified interim efficacy analysis met predefined futility criteria. SA4Ag showed no efficacy (0.0%) in preventing postoperative S. aureus infection (14 cases in each group through postoperative day 90), despite inducing robust functional immune responses to each antigen compared with placebo. Colonization rates across groups were similar through postoperative day 180. Local reactions and systemic events were mostly mild or moderate in severity, with AEs reported at similar frequencies across groups. In patients undergoing elective spinal fusion surgical procedures, SA4Ag was safe and well tolerated but, despite eliciting substantial antibody responses that blocked key S. aureus virulence mechanisms, was not efficacious in preventing S. aureus infection. Clinical Trials Registration. NCT02388165.
- Open Access
- 26 October 2022
- Published by MDPI AG in Neurology International
- Vol. 14  (4) , 875-883
Twelve-Month Results from a Prospective Clinical Study Evaluating the Efficacy and Safety of Cellular Bone Allograft in Subjects Undergoing Lumbar Spinal Fusion
Background: While autologous bone grafts remain the gold standard for spinal fusion procedures, harvesting autologous bone is associated with significant complications, including donor site infection, hematomas, increased operative time, and prolonged pain. Cellular bone allograft (CBA) presents an alternative to autologous bone harvesting, with a favorable efficacy and safety profile. The current study further investigates CBA as an adjunct to lumbar spinal fusion procedures. Methods: A prospective, multicenter, open-label clinical study was conducted in subjects undergoing lumbar spinal fusion with CBA (NCT 02969616). Radiographic fusion status was assessed by an independent review of dynamic radiographs and CT scans. Clinical outcome measures included the Oswestry Disability Index (ODI) and visual analogue scale (VAS) for back and leg pain. Adverse-event reporting was conducted throughout 12 months of follow-up. Available subject data at 12 months were analyzed. Results: A total of 274 subjects were enrolled into the study, with available data from 201 subjects (73.3%) who completed 12 months of postoperative radiographic and clinical evaluation at the time of analysis. Subjects had a mean age of 60.2 ± 11.5 years. A higher number of women (n = 124, 61.7%) than men (n = 77, 38.3%) were enrolled, with a collective mean BMI of 30.6 + 6.5 kg/m2 (range 18.0–51.4). At month 12, successful fusion was achieved in 90.5% of subjects. A significant (p < 0.001) improvement in ODI, VAS-back, and VAS-leg clinical outcomes was also observed compared to baseline scores. One adverse event related to CBA (postoperative radiculopathy) was reported, with surgical exploration demonstrating interbody extrusion of graft material. This subject reported successful fusion at month 12. Conclusions: CBA represents a viable substitute for harvesting of autograft alone with a high rate of successful fusion and significant improvements in subject-reported outcomes, such as pain and disability. Positive benefit was observed in subjects reporting single and multiple risk factors for pseudoarthrosis.
- 26 October 2022
- Published by MDPI AG in Neurology International
- Vol. 14  (4) , 875-883
Open AccessTwelve-Month Results from a Prospective Clinical Study Evaluating the Efficacy and Safety of Cellular Bone Allograft in Subjects Undergoing Lumbar Spinal Fusion
Background: While autologous bone grafts remain the gold standard for spinal fusion procedures, harvesting autologous bone is associated with significant complications, including donor site infection, hematomas, increased operative time, and prolonged pain. Cellular bone allograft (CBA) presents an alternative to autologous bone harvesting, with a favorable efficacy and safety profile. The current study further investigates CBA as an adjunct to lumbar spinal fusion procedures. Methods: A prospective, multicenter, open-label clinical study was conducted in subjects undergoing lumbar spinal fusion with CBA (NCT 02969616). Radiographic fusion status was assessed by an independent review of dynamic radiographs and CT scans. Clinical outcome measures included the Oswestry Disability Index (ODI) and visual analogue scale (VAS) for back and leg pain. Adverse-event reporting was conducted throughout 12 months of follow-up. Available subject data at 12 months were analyzed. Results: A total of 274 subjects were enrolled into the study, with available data from 201 subjects (73.3%) who completed 12 months of postoperative radiographic and clinical evaluation at the time of analysis. Subjects had a mean age of 60.2 ± 11.5 years. A higher number of women (n = 124, 61.7%) than men (n = 77, 38.3%) were enrolled, with a collective mean BMI of 30.6 + 6.5 kg/m2 (range 18.0–51.4). At month 12, successful fusion was achieved in 90.5% of subjects. A significant (p < 0.001) improvement in ODI, VAS-back, and VAS-leg clinical outcomes was also observed compared to baseline scores. One adverse event related to CBA (postoperative radiculopathy) was reported, with surgical exploration demonstrating interbody extrusion of graft material. This subject reported successful fusion at month 12. Conclusions: CBA represents a viable substitute for harvesting of autograft alone with a high rate of successful fusion and significant improvements in subject-reported outcomes, such as pain and disability. Positive benefit was observed in subjects reporting single and multiple risk factors for pseudoarthrosis.
- Open Access
- 19 October 2022
- Published by SAGE Publications in Global Spine Journal
- Vol. 14  (3) , 949-955
No Difference in Two-Year Revisions Between Hybrid Fusion and Two-Level Anterior Discectomy and Fusion: A National Database Study
Study Design: Retrospective Cohort Objective: This study utilized a large national database to compare two-year revision rates, in addition to complications and costs, of hybrid surgery (HS) compared to two-level anterior cervical discectomy and fusion (ACDF). Methods: This study used the PearlDiver Mariner dataset selecting for patients aged 18 and older who had at least 90-day active longitudinal follow-up who underwent two-level ACDF or two-level Hybrid surgery (single level ACDF and single level CDA). Patients with prior spinal trauma, infection, cancer, or posterior fusion were excluded. Primary outcomes measures were 90-day major and minor medical complications, ED visits, readmissions, as well as two-year revisions. Patients were also assessed for postoperative dysphagia, incidental durotomy, vascular injury, 90-day surgical site, and implant complications. Additionally, hospitalization and postoperative costs were evaluated. Results: There were 4570 two-level ACDF surgeries and 888 hybrid surgeries. After matching the cohorts, no statistical differences in demographics were found. There were no differences in reoperation rates at all measured time points nor 2-year complications. HS had a lower incidence of major (1.6% vs 3.1%, P = .003) and minor complications (3.0% vs 4.6%, P = .009) than ACDF. 90-day readmission was lower in the HS cohort (2.8% vs 4.2%), P = .024. HS was associated with reduced hospitalization costs -$2614 (-$3916 to -$904, P < .001). 3516 patients had ACDF, and 699 had HS with at least 2 years of follow-up. Conclusion: Hybrid surgery is a safe and effective surgical treatment for cervical disease in appropriately selected patients.
- 19 October 2022
- Published by SAGE Publications in Global Spine Journal
- Vol. 14  (3) , 949-955
Open AccessNo Difference in Two-Year Revisions Between Hybrid Fusion and Two-Level Anterior Discectomy and Fusion: A National Database Study
Study Design: Retrospective Cohort Objective: This study utilized a large national database to compare two-year revision rates, in addition to complications and costs, of hybrid surgery (HS) compared to two-level anterior cervical discectomy and fusion (ACDF). Methods: This study used the PearlDiver Mariner dataset selecting for patients aged 18 and older who had at least 90-day active longitudinal follow-up who underwent two-level ACDF or two-level Hybrid surgery (single level ACDF and single level CDA). Patients with prior spinal trauma, infection, cancer, or posterior fusion were excluded. Primary outcomes measures were 90-day major and minor medical complications, ED visits, readmissions, as well as two-year revisions. Patients were also assessed for postoperative dysphagia, incidental durotomy, vascular injury, 90-day surgical site, and implant complications. Additionally, hospitalization and postoperative costs were evaluated. Results: There were 4570 two-level ACDF surgeries and 888 hybrid surgeries. After matching the cohorts, no statistical differences in demographics were found. There were no differences in reoperation rates at all measured time points nor 2-year complications. HS had a lower incidence of major (1.6% vs 3.1%, P = .003) and minor complications (3.0% vs 4.6%, P = .009) than ACDF. 90-day readmission was lower in the HS cohort (2.8% vs 4.2%), P = .024. HS was associated with reduced hospitalization costs -$2614 (-$3916 to -$904, P < .001). 3516 patients had ACDF, and 699 had HS with at least 2 years of follow-up. Conclusion: Hybrid surgery is a safe and effective surgical treatment for cervical disease in appropriately selected patients.
- 24 August 2022
- Published by Wolters Kluwer Health in Clinical Spine Surgery
- Vol. 36  (7) , E300-E305
Treatment of Hepatitis C Virus Prior to Posterior Lumbar Fusion
Study Design: Retrospective cohort. Objective: To analyze and confirm the rates of postoperative complications of patients with hepatitis C virus (HCV) undergoing primary posterior lumbar fusion (PLF) and assess whether treatment of HCV before surgery reduces complications. Background Context: HCV causes chronic disease, leading to increased risk of cirrhosis and chronic illness. Currently, there is a lack of research regarding whether the patient’s HCV is a modifiable risk factor for postoperative complications after spinal procedures. Methods: The Mariner database was utilized to find patients from 2010 to 2018 undergoing PLF with active follow-up for a year. Cases involving same-day revision procedures and patients with a history of spine, infection, trauma, human immunodeficiency virus, hepatitis B, or neoplasm were excluded. Patients with a history of HCV diagnosis were identified and further stratified whether they had prior treatment using the national drug codes for antiviral, interferons, or ribavirin. Patients with HCV were matched with those without respect to age, sex, and comorbidity of burden. Outcome measured included 90-day medical complications, infection, readmission, and 1-year reoperation. Results: There were 2,129 patients with HCV and 10,544 patients in the matched control group who underwent primary PLF. Out of the 2,129 patients, 469 (22.0.%) were treated with HCV medications before surgery. Patients with prior history of HCV had a significantly increased risk of wound complications (4.4% vs. 3.2%, odds ratio 1.56, 95% confidence interval 1.24–1.96, P=0.009), and infection (7.7% vs. 5.7%, odds ratio 1.26, 95% confidence interval 1.07–1.53, P=0.009) within 90 days of surgery. Patients treated before surgery did not have a difference in major (P=0.205) or minor medical complications (P=0.681) after surgery. Conclusions: Patients with prior history of HCV are at increased risk for many complications after surgery; however, this risk factor does not seem to be modifiable as the treatment group did not experience any improvement in postoperative outcomes. Level of Evidence: Level III.
- 24 August 2022
- Published by Wolters Kluwer Health in Clinical Spine Surgery
- Vol. 36  (7) , E300-E305
Treatment of Hepatitis C Virus Prior to Posterior Lumbar Fusion
Study Design: Retrospective cohort. Objective: To analyze and confirm the rates of postoperative complications of patients with hepatitis C virus (HCV) undergoing primary posterior lumbar fusion (PLF) and assess whether treatment of HCV before surgery reduces complications. Background Context: HCV causes chronic disease, leading to increased risk of cirrhosis and chronic illness. Currently, there is a lack of research regarding whether the patient’s HCV is a modifiable risk factor for postoperative complications after spinal procedures. Methods: The Mariner database was utilized to find patients from 2010 to 2018 undergoing PLF with active follow-up for a year. Cases involving same-day revision procedures and patients with a history of spine, infection, trauma, human immunodeficiency virus, hepatitis B, or neoplasm were excluded. Patients with a history of HCV diagnosis were identified and further stratified whether they had prior treatment using the national drug codes for antiviral, interferons, or ribavirin. Patients with HCV were matched with those without respect to age, sex, and comorbidity of burden. Outcome measured included 90-day medical complications, infection, readmission, and 1-year reoperation. Results: There were 2,129 patients with HCV and 10,544 patients in the matched control group who underwent primary PLF. Out of the 2,129 patients, 469 (22.0.%) were treated with HCV medications before surgery. Patients with prior history of HCV had a significantly increased risk of wound complications (4.4% vs. 3.2%, odds ratio 1.56, 95% confidence interval 1.24–1.96, P=0.009), and infection (7.7% vs. 5.7%, odds ratio 1.26, 95% confidence interval 1.07–1.53, P=0.009) within 90 days of surgery. Patients treated before surgery did not have a difference in major (P=0.205) or minor medical complications (P=0.681) after surgery. Conclusions: Patients with prior history of HCV are at increased risk for many complications after surgery; however, this risk factor does not seem to be modifiable as the treatment group did not experience any improvement in postoperative outcomes. Level of Evidence: Level III.
- 25 February 2022
- Published by Elsevier in World Neurosurgery
- Vol. 162, e91-e98
Penicillin Allergy in Spine Surgery: Increased Rates of Sepsis, Emergency Room Visits, and Readmission
- 25 February 2022
- Published by Elsevier in World Neurosurgery
- Vol. 162, e91-e98
Penicillin Allergy in Spine Surgery: Increased Rates of Sepsis, Emergency Room Visits, and Readmission